Classification of Medicines

Pursuant to section 106(1) of the Medicines Act 1981, I, Chris James, Group Manager, Medsafe, Ministry of Health, acting under delegated authority, hereby declare the following:

1. The medicines listed in Schedule 1 to this notice are classified as prescription medicines.
2. The medicines listed in Schedule 2 to this notice are classified as restricted medicines.
3. The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines.

Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.

Unless specific reference is made otherwise, every reference applies also to medicines that are:

a. preparations and admixtures containing any proportion of any substance listed in the notice.
b. salts and esters of any substance listed in the notice.
c. preparations or extracts of biological materials listed in the notice.
d. salts or oxides of elements listed in the notice.

Unless specific reference is made otherwise, every reference to a medicine applies:

i. if the medicine is in an injection or eye preparation, to any concentration of that medicine; and
ii. if the medicine is not in an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

Brigatinib
Budesonide; except when specified elsewhere in this notice
Crisaborole
Fluticasone; except when specified elsewhere in this notice
Lanadelumab
Romosozumab
Safinamide
Tilmanocept
Tivozanib

Schedule 3

Pharmacy-only Medicines

Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril)

Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose)

Dated this 10th day of July 2019.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health.

2019-go3281 12-07-2019 15:00